Rituximab 375 mg/m^2
26866138-LYM-3002
Phase 3 small_molecule completed
Quick answer
Rituximab 375 mg/m^2 for Mantle Cell Lymphoma is a Phase 3 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Mantle Cell Lymphoma
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed